Consumer Marketing Manager

WEST, OnSide and GSK partner to inspire the next generation in STEM. Home - uncategorized - WEST, OnSide and GSK partner to inspire the next generation in STEM. WEST Youth Zone, company is proud to announce a new partnership with GSK, uniting its shared ambition to inspire young people and open up opportunities in science, technology, engineering and maths (STEM). As a global biopharma company, GSK, will support the partnership with the creation of dedicated Maker Zones at Unitas, Barnet Youth Zone and WEST, Hammersmith & Fulham Youth Zone. These zones will provide engaging and accessible spaces where young people can explore STEM through hands-on activities. Alongside this, a pilot programme of intensive STEM workshops will be delivered in May and October, in collaboration with The Franklin Institute, a renowned science and technology learning museum in Philadelphia, USA. Experts will travel from the United States to work directly with young people and train Youth Zone staff, helping to embed high-quality STEM provision for the long term. This partnership builds on a longstanding relationship between GSK and WEST, which began in 2018, and marks an exciting new phase as WEST Youth Zone, company work with OnSide to expand the reach and impact of this initiative. By combining GSK's expertise and commitment to science with OnSide's national network of Youth Zones, this programme aims to make STEM relevant, exciting and achievable for all young people, particularly those who may not otherwise have access to these opportunities. Stephanie Dean, Director of Programmes, Charitable Investments at GSK said: "Through engaging, practical activities that make scientific concepts tangible, our partnership helps students explore the range of STEM careers available to them. Science drives what we do at GSK every day, and we're delighted to support and inspire future scientists. Activities like the 'Be a Chemist' programme will introduce young people to a range of real-world STEM careers, helping to broaden horizons and raise aspirations." Employee engagement is also a key focus, with colleagues from three GSK sites volunteering their time. They will bring additional skills, insight and inspiration to young people participating in the programme. Looking ahead, its ambition is to develop a scalable model that can be rolled out across the wider OnSide Network, reaching thousands more young people and helping to build a more inclusive future STEM workforce. Jamie Masraff, CEO at OnSide said: "We're incredibly grateful to GSK for their support and commitment to helping young people access opportunities in STEM. Through our Youth Zones, we're creating spaces where young people can discover what they're capable of, and by bringing STEM to life in a hands-on, accessible way, this programme will open up new possibilities and future pathways. We're proud to be working with GSK, Unitas and WEST to inspire the next generation and help more young people find their passion and their purpose."

GSK contract, UK clearance for CTVQ, and ASX 200 inclusion. 5.93 +0.09 (+1.54%) ASX announcement ASX: 4DX The future of lung health Melbourne Level 7 Melbourne Connect 700 Swanston St reet Carlton V IC 30 53 Los Angeles 21255 Burbank Boulevard Suite 1 20 Woodland Hills CA 91367 4DMedical L imi t e d ABN: 31 161 684 831 Email: [email protected] 1 Tel: +61 (3) 9545 5940 Tel: +1 (818) 403 - 8490 www.4 DM edical.com GSK contract, UK clearance for CT:VQ (TM), and ASX 200 inclusion 20 April 20 26 Highlights - Contract executed with GlaxoSmithKline (GSK), one of the world's largest pharmaceutical companies, to supply 4DMedical's functional lung imaging analytics in support of pulmonary drug development - CT:VQ (TM) receives UKCA certification for clinical use in the United Kingdom, expanding 4DMedical's European footprint following CE Mark certification in March 2026 - UK clearance opens access to one of the world's most developed diagnostic imaging markets, with millions of chest CT scans performed annually across respiratory, oncology and acute care pathways - Coronary Artery Calcium (CAC) analysis cleared in Canada, coinciding with 4DMedical's participation at the Canadian Association of Radiologists (CAR) Annual Scientific Meeting in Montreal - CMS establishes a new US reimbursement pathway for AI - based opportunistic coronary calcium analysis from routine chest CT scans, enabling scalable clinical and commercial adoption - 4DMedical included in the S&P/ASX 200 Index, effective prior to the open of trading today Melbourne, Australia, 20 April 20 26 - 4DMedical Limited (ASX: 4DX, "4DMedical" or the "Company"), a global leader in respiratory imaging technology, today announce s a series of commercial, regulatory and corporate milestones that further expand global market access and validate demand for its advanced cardiopulmonary imaging analytics platform. Strategic pharmaceutical engagement with GSK 4DMedical has entered a contractual engagement with GlaxoSmithKline (GSK), in association with leading imaging data platform Flywheel Exchange, to provide its proprietary quantitative lung imaging analytics in support of pulmonary drug development and clin ical research. Under the one - year agreement, 4DMedical will supply advanced lung imaging biomarkers from its software analytics platform, enabling sensitive, quantitative assessment of lung structure and function across clinical trial cohorts. The contract commences on 1 May 2026. The contract value is commercially confidential and is not individually material. The engagement with one of the world's largest pharmaceutical companies reflects increasing adoption of 4DMedical's analytics platform by global biopharmaceutical companies seeking scalable, reproducible imaging endpoints to improve trial efficiency, patie nt stratification, and longitudinal disease assessment. The GSK contract builds on 4DMedical's established pharmaceutical relationships, including its ongoing engagement with AstraZeneca, and reinforces the Company's position as a preferred provider of qua ntitative imaging analytics for respiratory drug development. UK clearance for CT:VQ (TM) expands European footprint CT:VQ (TM) continues to be 4DMedical's primary commercial growth driver in the United States, where FDA clearance has enabled deployment across leading Academic Medical Centers (AMCs) and positioned the technology at the forefront of next - generation functional lung imaging. CT:VQ (TM) is now deployed at six leading U.S. AMCs, with additional institutions actively evaluating the technology. (C) 4DMedical Limited 2 4DMedical.com The Company is pleased to advise that, following the receipt of CE Mark certification in March 2026, CT:VQ (TM) has now obtained UKCA certification for clinical use in the United Kingdom, under the regulatory oversight of the Medicines and Healthcare products Regulatory Agency (MHRA). This regulatory clearance allows for the immediate commercial deployment of CT:VQ (TM) across both public and private healthcare providers within the UK. The UK represents one of the world's most developed diagnostic imaging environments. Millions of chest CT scans are performed annually, with CT forming a core diagnostic tool for lung cancer screening, COPD, interstitial lung disease, pulmonary embolism, a nd acute care workflows. CT:VQ (TM) is uniquely positioned to integrate into these established pathways by delivering quantitative ventilation and perfusion insights from routine non - contrast CT scans, without the complexity or constraints of nuclear medicine. Europe and the UK play a critical role in shaping global respiratory medicine and imaging practice. Institutions such as the Royal Brompton Hospital in London, where 4DMedical clinical research is underway, are internationally recognised centres of excellence in cardiopulmonary research and clinical care, with strong collaborative ties to North American AMCs. UK clearance enables 4DMedical to engage directly with leading European and UK clinicians, support investigator - initiated research, and contribute to the global clinical evidence base underpinning CT:VQ (TM). This engagement is complementary to the Company's US commercial strategy and reinforces the long - term clinical credibility of its platform. With UKCA and CE Mark certifications now in hand, 4DMedical holds regulatory clearance for CT:VQ (TM) across the United States, the European Union, the United Kingdom, Canada, and New Zealand. CAC clearance in Canada The Company confirms that its Coronary Artery Calcium (CAC) analysis solution has received regulatory clearance from Health Canada, permitting clinical use across Canadian healthcare institutions. This milestone coincides with 4DMedical's attendance at the Canadian Association of Radiologists (CAR) Annual Scientific Meeting in Montreal over the weekend, where the Company presented its expanding cardiopulmonary imaging portfolio to radiologists, researchers and health system leaders. 1 1 1 REGULATORY COMPLIANCE - REGULATORY STATUS FDA (USA) CE Mark (EU) TGA (AU) CMDR (Canada) MHRA (UK) Medsafe (NZ) ANVISA (Brazil) CAC ü ü Under review ü CT LVAS ü ü ü ü ü CT:VQ ü ü Under review ü ü ü IQ - UIP ü Under review LDA ü ü ü ü ü ü LTA ü ü ü ü ü PHA ü * RV/LV ü ü ü ü XV LVAS ü ü ü 4DMedical Limited (ASX:4DX) is a medical technology company aiming to deliver the global gold standard in respiratory diagnostics for all... 4DX Profile Links 4DX Information Share Price: 24hr Change: 24hr Change %: Market Cap: Join Listcorp to create a personalised news feed, follow your favourite companies, save useful news, and more. 13 Apr 2026 10 Apr 2026 27 Mar 2026